These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36059457)

  • 1. Immunosuppressant exposure confounds gene expression analysis in systemic lupus erythematosus.
    Northcott M; Gearing LJ; Bonin J; Koelmeyer R; Hoi A; Hertzog PJ; Morand EF
    Front Immunol; 2022; 13():964263. PubMed ID: 36059457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
    Yap DYH; Chan TM
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th-17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis.
    AlFadhli S; AlFailakawi A; Ghanem AA
    Int J Rheum Dis; 2016 May; 19(5):512-20. PubMed ID: 25496163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil.
    Akthar M; Nair N; Carter LM; Vital EM; Sutton E; McHugh N; ; ; Bruce IN; Reynolds JA
    Arthritis Res Ther; 2023 Jun; 25(1):111. PubMed ID: 37391799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus.
    Catalina MD; Bachali P; Geraci NS; Grammer AC; Lipsky PE
    Commun Biol; 2019; 2():140. PubMed ID: 31044165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers.
    Chasset F; Ribi C; Trendelenburg M; Huynh-Do U; Roux-Lombard P; Courvoisier DS; Chizzolini C;
    Rheumatology (Oxford); 2020 Nov; 59(11):3468-3478. PubMed ID: 32375176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis.
    Friebus-Kardash J; Trendelenburg M; Eisenberger U; Ribi C; Chizzolini C; Huynh-Do U; Lang KS; Wilde B; Kribben A; Witzke O; Dolff S; Hardt C
    BMC Nephrol; 2019 Nov; 20(1):430. PubMed ID: 31752784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs.
    Garantziotis P; Nikolakis D; Doumas S; Frangou E; Sentis G; Filia A; Fanouriakis A; Bertsias G; Boumpas DT
    Front Immunol; 2022; 13():860726. PubMed ID: 35615355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
    Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.
    Lewandowski LB; Schanberg LE; Thielman N; Phuti A; Kalla AA; Okpechi I; Nourse P; Gajjar P; Faller G; Ambaram P; Reuter H; Spittal G; Scott C
    Lupus; 2017 Feb; 26(2):186-194. PubMed ID: 27488473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis.
    Jourde-Chiche N; Whalen E; Gondouin B; Speake C; Gersuk V; Dussol B; Burtey S; Pascual V; Chaussabel D; Chiche L
    Rheumatology (Oxford); 2017 Mar; 56(3):477-487. PubMed ID: 28031441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis.
    Chan RW; Lai FM; Li EK; Tam LS; Chow KM; Li PK; Szeto CC
    Nephrol Dial Transplant; 2006 Jun; 21(6):1534-40. PubMed ID: 16449281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus.
    Lindblom J; Toro-Domínguez D; Carnero-Montoro E; Beretta L; Borghi MO; Castillo J; Enman Y; ; Mohan C; Alarcón-Riquelme ME; Barturen G; Parodis I
    J Autoimmun; 2023 Apr; 136():103025. PubMed ID: 36996699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients.
    Wang H; Lan L; Chen J; Xiao L; Han F
    Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35973743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD14 (C-159T) polymorphism is associated with increased susceptibility to SLE, and plasma levels of soluble CD14 is a novel biomarker of disease activity: A hospital-based case-control study.
    Panda AK; Tripathy R; Das BK
    Lupus; 2021 Feb; 30(2):219-227. PubMed ID: 33176568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One year in review 2017: systemic lupus erythematosus.
    La Paglia GMC; Leone MC; Lepri G; Vagelli R; Valentini E; Alunno A; Tani C
    Clin Exp Rheumatol; 2017; 35(4):551-561. PubMed ID: 28721860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.